Slx Inhibitors
Slx inhibitors are a class of chemical compounds that specifically target and inhibit the activity of Slx proteins, which are involved in the regulation of DNA repair and recombination processes. The Slx family includes several key proteins, such as Slx1 and Slx4, which play critical roles in maintaining genome integrity by facilitating the resolution of DNA structures that arise during replication and recombination. These proteins are particularly important in the context of resolving Holliday junctions and other complex DNA intermediates that can form during homologous recombination and DNA repair. By participating in these processes, Slx proteins help ensure accurate DNA replication and prevent the accumulation of DNA damage that could lead to genomic instability.
The mechanism of action of Slx inhibitors generally involves binding to specific domains within the Slx proteins, preventing them from interacting with their substrates or partner proteins necessary for their function in DNA repair. Some inhibitors may compete with the natural substrates of Slx proteins, while others could induce conformational changes that diminish their enzymatic activity. By inhibiting Slx, these compounds can disrupt the normal resolution of DNA structures, leading to an increase in unresolved DNA intermediates and potential challenges in maintaining genomic stability. Research into Slx inhibitors provides valuable insights into the complex mechanisms of DNA repair and recombination, highlighting the essential roles that Slx proteins play in safeguarding genetic information. Understanding how Slx proteins operate and how their inhibition affects DNA metabolism contributes to a broader comprehension of the molecular networks that govern cellular responses to DNA damage and the maintenance of genomic integrity across various biological contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective inhibitor of Mitogen-Activated Protein Kinase Kinase (MEK), a part of the MAPK/ERK pathway. By inhibiting MEK, this compound prevents the phosphorylation and activation of ERK, which can lead to decreased activity of downstream targets including Slx if Slx's activity is dependent on ERK signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). PI3K is pivotal for many cellular functions, including cell growth and survival signals. By inhibiting PI3K, LY294002 can reduce the activation of AKT, potentially affecting Slx activity if Slx is downstream of AKT signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. The p38 MAP kinase pathway is involved in inflammatory responses and stress. By inhibiting p38, SB203580 could decrease the activity of Slx if it is modulated by stress-activated signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that binds to FK506-binding protein (FKBP12) and inhibits the mTORC1 complex, which is essential for protein synthesis and cell growth. Inhibition of mTORC1 can downregulate Slx if its activity is linked to mTOR signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, impairing the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 prevents the activation of ERK, which could subsequently lead to a reduction in Slx activity if Slx is regulated by the ERK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By blocking PI3K activity, Wortmannin can impede the PI3K/AKT pathway, which could result in decreased Slx activity if Slx functions downstream of this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in controlling gene expression related to apoptosis and cell proliferation. Inhibiting JNK could reduce Slx activity if Slx is controlled by pathways involving JNK activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated, coiled-coil containing protein kinase (ROCK). By inhibiting ROCK, this compound can alter cytoskeleton organization and cell motility, which could inhibit Slx if Slx is involved in these cellular processes. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
ZM 336372 is a potent inhibitor of RAF kinases, which are upstream of the MEK/ERK pathway. By inhibiting RAF, this compound could reduce the activation of downstream targets including Slx if Slx is regulated by RAF kinase activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. EGFR signaling is important for cell proliferation and survival. Inhibiting EGFR could decrease Slx activity if Slx is involved in EGFR signaling pathways. | ||||||